US 6423699
Combination therapies using benzimidazolones
expired A61KA61K31/415A61K31/535
Quick answer
US patent 6423699 (Combination therapies using benzimidazolones) held by Ligand Pharmaceuticals Incorporated expires Mon Jul 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.
Key facts
- Applicant
- Ligand Pharmaceuticals Incorporated
- Grant date
- Tue Jul 23 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K31/415, A61K31/535, A61K31/54, A61K31/56